Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 542 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading MOST POPULAR Trial Suggests Expanded Role for Blinatumomab in Treating ALL January 25, 2023 “Scars are Tattoos with Better Stories” July 21, 2021 COVID-19 Vaccine Myth Busters January 28, 2021 EMA Recommends Extension of Indications for Blinatumomab June 9, 2021 Load more HOT NEWS First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... Hockey Fan Dubbed Hero After Saving Equipment Manager’s Life Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer Oncotype DX Breast Cancer Test May Be Less Accurate for Black...
